(Q79744901)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

title

Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Stefan Leucht

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

John M Davis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

John M Kane

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Stefan Wagenpfeil

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

7 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

published in

Neuropsychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

1903-1910

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287825%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301325

25 December 2019

exact match

0 references

cites work

Remission in schizophrenia: proposed criteria and rationale for consensus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Clinical profile of an atypical antipsychotic: risperidone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Meta-analysis: principles and procedures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Time course for antipsychotic treatment response in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Clinical implications of Brief Psychiatric Rating Scale scores

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

What does the PANSS mean?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Linking the PANSS, BPRS, and CGI: clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301325

7 January 2021